PRESS RELEASE : MIG funds increases BioNTech dividend payments to a record EUR600 million

DGAP-News: MIG Verwaltungs AG / Key word(s): Dividend 
MIG funds increases BioNTech dividend payments to a record EUR600 million 
2021-02-04 / 08:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
MIG funds increases BioNTech dividend payments to a record EUR600 million 
Munich, Germany, 04 February 2021 
MIG AG, is pleased to announce that its investment funds, MIG Fonds, are paying out another record distribution from 
its holdings in the German biotech company BioNTech SE. The venture capital firm is a founding investor of BioNTech in 
2008 and, with support from further investors, led the biotech's initial public offering (IPO) on NASDAQ in 2019. With 
the current distribution, MIG investors will receive close to EUR340 million. In addition to 2020 dividends of EUR260 
million, the total distribution amount from MIGs investments in BioNTech totals about EUR600 million to date. The current 
distribution sets a new record as the highest single payout in the firm's history. 
Kristian Schmidt-Garve, General Partner of MIG AG, said: "As venture capitalists invested in BioNTech from the very 
beginning, MIG funds and its clients, have contributed significantly to the development of the company as a leading 
European biotech. We are proud of our portfolio company's enormous success and their contribution to overcoming the 
global pandemic with the world's first COVID-19 mRNA vaccine. We are also very pleased that we were able to realize 
substantial returns for our investors, representing a considerate multiple of their initial investment." 
About MIG AG 
MIG Verwaltungs AG (MIG AG), Munich, is one of the leading German VC investors. MIG invests through MIG funds in young 
deep tech and life sciences companies in German-speaking Europe and beyond. To date, the company has invested around EUR 
580 million in over 40 companies. MIG's portfolio companies develop innovations in biopharmaceuticals, AI / machine 
learning, quantum technologies, digitization / IOT, medtech and digital health. The MIG investment portfolio currently 
consists of 28 companies. 
MIG's investment team consists of a committed group of experts of engineers, biologists, scientists and investors who 
use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. 
Their reputation, their experience and their network enable excellent access to companies, institutions and 
decision-makers to support the growth of their portfolio companies. 
In recent years, MIG AG has successfully sold it's portfolio companies SuppreMol (to Baxter in 2015), sunhill 
technologies (to Volkswagen in 2015), Ganymed (to Astellas in 2016) and Siltectra (to Infineon in 2018) and leads Brain 
(in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges. 
For further information please visit: www.mig.ag, www.mig-fonds.de 
Contacts: 
Kristian Schmidt-Garve 
General Partner MIG AG 
[phone] 
[e-mail] 
MC Services (for media inquiries) 
Julia Hofmann 
[phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-02-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1165577 2021-02-04

(END) Dow Jones Newswires

February 04, 2021 02:04 ET (07:04 GMT)